Now showing items 1-6 of 6

    • Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer. 

      Hermanova, I; Zúñiga-García, P; Caro-Maldonado, A; Fernandez-Ruiz, S; Salvador, F; Martín-Martín, N; Zabala-Letona, A; Nuñez-Olle, M; Torrano, V; Camacho, L; Lizcano, JM; Talamillo, A; Carreira, S; Gurel, B; Cortazar, AR; Guiu, M; López, JI; Martinez-Romero, A; Astobiza, I; Valcarcel-Jimenez, L; Lorente, M; Arruabarrena-Aristorena, A; Velasco, G; Gomez-Muñoz, A; Suárez-Cabrera, C; Lodewijk, I; Flores, JM; Sutherland, JD; Barrio, R; de Bono, JS; Paramio, JM; Trka, J; Graupera, M; Gomis, RR; Carracedo, A (2020-06)
      Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form ...
    • Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. 

      Zafeiriou, Z; Bianchini, D; Chandler, R; Rescigno, P; Yuan, W; Carreira, S; Barrero, M; Petremolo, A; Miranda, S; Riisnaes, R; Rodrigues, DN; Gurel, B; Sumanasuriya, S; Paschalis, A; Sharp, A; Mateo, J; Tunariu, N; Chinnaiyan, AM; Pritchard, CC; Kelly, K; de Bono, JS (2019-01)
      Platinum-based regimens have not been proved to increase survival from advanced prostate cancer (PCa). Incontrovertible evidence that a proportion of prostate cancers have homologous recombination DNA (HRD) repair defects, ...
    • Genomics of lethal prostate cancer at diagnosis and castration resistance. 

      Mateo, J; Seed, G; Bertan, C; Rescigno, P; Dolling, D; Figueiredo, I; Miranda, S; Nava Rodrigues, D; Gurel, B; Clarke, M; Atkin, M; Chandler, R; Messina, C; Sumanasuriya, S; Bianchini, D; Barrero, M; Petermolo, A; Zafeiriou, Z; Fontes, M; Perez-Lopez, R; Tunariu, N; Fulton, B; Jones, R; McGovern, U; Ralph, C; Varughese, M; Parikh, O; Jain, S; Elliott, T; Sandhu, S; Porta, N; Hall, E; Yuan, W; Carreira, S; de Bono, JS (2020-04)
      The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, ...
    • Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. 

      Mateo, J; Porta, N; Bianchini, D; McGovern, U; Elliott, T; Jones, R; Syndikus, I; Ralph, C; Jain, S; Varughese, M; Parikh, O; Crabb, S; Robinson, A; McLaren, D; Birtle, A; Tanguay, J; Miranda, S; Figueiredo, I; Seed, G; Bertan, C; Flohr, P; Ebbs, B; Rescigno, P; Fowler, G; Ferreira, A; Riisnaes, R; Pereira, R; Curcean, A; Chandler, R; Clarke, M; Gurel, B; Crespo, M; Nava Rodrigues, D; Sandhu, S; Espinasse, A; Chatfield, P; Tunariu, N; Yuan, W; Hall, E; Carreira, S; de Bono, JS (2020-01)
      Background Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and ...
    • Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. 

      Paschalis, A; Sheehan, B; Riisnaes, R; Rodrigues, DN; Gurel, B; Bertan, C; Ferreira, A; Lambros, MBK; Seed, G; Yuan, W; Dolling, D; Welti, JC; Neeb, A; Sumanasuriya, S; Rescigno, P; Bianchini, D; Tunariu, N; Carreira, S; Sharp, A; Oyen, W; de Bono, JS (2019-10)
      Background Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate cancer (PC) expression has theranostic utility. Objective To elucidate PC PSMA expression and associate this with defective DNA damage repair ...
    • TOPARP-B: A Randomised Phase 2 Trial Evaluating Two Doses of Olaparib Against Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations 

      Hall, E; De Bono, J; Porta, N; Miranda, S; Flohr, P; Ferreira, A; Riisnaes, R; Chatfield, P; Carreira, S; Yuan, W; Tunariu, N; Espinasse, A; Crespo, M; Nava Rodrigues, D; Gurel, B; Clarke, M; Curcean, A; Pereira, AR; Fowler, G; Rescigno, P; Ebbs, B; Bertan, C; Seed, G; Figueiredo, I